UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

被引：0

作者：

E Martinez-Balibrea

A Abad

A Martínez-Cardús

A Ginés

M Valladares

M Navarro

E Aranda

E Marcuello

M Benavides

B Massutí

A Carrato

L Layos

J L Manzano

V Moreno

机构：

[1] Medical Oncology Service,Department of Clinical Sciences

[2] Institut Català d'Oncologia,undefined

[3] Hospital Germans Trias I Pujol. C/Ctra. Canyet s/n,undefined

[4] Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (FIGTP). C/Ctra. De Can Ruti,undefined

[5] camí de les escoles s/n,undefined

[6] Medical Oncology Service,undefined

[7] Complejo Hospitalario Universitario Juan Canalejo,undefined

[8] C/Lugar Xubias De Arriba 84,undefined

[9] A Coruña 15006,undefined

[10] Spain,undefined

[11] Medical Oncology Service,undefined

[12] Institut Català d'Oncologia,undefined

[13] Hospital Duran I Reynals,undefined

[14] Avda. Gran Vía s/n Km 2.7,undefined

[15] L'Hospitalet de Llobregat 08907,undefined

[16] Spain,undefined

[17] Medical Oncology Service,undefined

[18] Hospital Universitario Reina Sofía,undefined

[19] C/Menéndez Pidal s/n,undefined

[20] Córdoba 14004,undefined

[21] Spain,undefined

[22] Medical Oncology Service,undefined

[23] Hospital de la Santa Creu I Sant Pau,undefined

[24] C/Sant Antoni Maria Claret,undefined

[25] 167,undefined

[26] Barcelona 08025,undefined

[27] Spain,undefined

[28] Medical Oncology Service,undefined

[29] Hospital Carlos Haya,undefined

[30] Avda. Carlos Haya s/n,undefined

[31] Medical Oncology Service,undefined

[32] Hospital General Universitario de Alicante,undefined

[33] Avda. Pintor Baeza s/n,undefined

[34] Medical Oncology Service,undefined

[35] Hospital General Universitario de Elche,undefined

[36] Camí Almassera 11,undefined

[37] Elche 03203,undefined

[38] Spain,undefined

[39] Biostatistics and Bioinformatics Unit,undefined

[40] Institut Català d'Oncologia,undefined

[41] Hospital Duran i Reynals,undefined

[42] Avda. Gran Vía s/n Km 2.7,undefined

[43] Institut d'Investigació de Bellvitge,undefined

[44] Feixa Llarga s/n,undefined

[45] University of Barcelona,undefined

[46] Feixa Llarga s/n,undefined

[47] L'Hospitalet de Llobregat 08907,undefined

[48] Spain,undefined

[49] Current address: Cancer Control and Prevention Service,undefined

[50] Institut Català d'Oncologia,undefined

来源：

British Journal of Cancer | 2010年 / 103卷

关键词：

colorectal; 5FU; irinotecan; toxicity; polymorphisms;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：581 / 589

页数：8

共 50 条

[31] Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and DPYD/tyms genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
Baldeo, Candice
Hughes, Caren
Shahjehan, Faisal
Kamatham, Saivaishnavi
Kasi, Pashtoon Murtaza
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[32] Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
Tsai, Hsiang-Lin
Chen, Yen-Cheng
Yin, Tzu-Chieh
Su, Wei-Chih
Chen, Po-Jung
Chang, Tsung-Kun
Li, Ching-Chun
Huang, Ching-Wen
Wang, Jaw-Yuan
ONCOLOGY RESEARCH, 2021, 29 (01) : 47 - 61
[33] UGT1A1 PROMOTER GENOTYPE AND TOXICITY IN PATIENTS WITH ADVANCED COLORECTAL CANCER TREATED WITH IRINOTECAN-CONTAINING CHEMOTHERAPY
Chiara, S.
Gargiulo, L.
Marroni, P.
Serra, M.
Tomasello, L.
Pastrone, I.
Paganuzzi, M.
Notaro, R.
ANNALS OF ONCOLOGY, 2004, 15 : 43 - 43
[34] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
Ocvirk, J.
Rebersek, M.
Boc, M.
ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
[35] Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis
Liang Xiao-bo
Hou Sheng-huai
Li Yao-ping
Wang Li-chun
Zhang Xin
Yang Jun
CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3314 - 3318
[36] Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
Glimelius, B
Ristamäki, R
Kjaer, M
Pfeiffer, P
Skovsgaard, T
Tveit, KM
Linné, T
Frödin, JE
Boussard, B
Oulid-Aïssa, D
Pyrhönen, S
ANNALS OF ONCOLOGY, 2002, 13 (12) : 1868 - 1873
[37] Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
Lang, Istvan
Koehne, Claus-Henning
Folprecht, Gunnar
Rougier, Philippe
Curran, Desmond
Hitre, Erika
Sartorius, Ute
Griebsch, Ingolf
Van Cutsem, Eric
EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) : 439 - 448
[38] Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy
Ding, Ke-Feng
Liu, Yue
Xiao, Qian
He, Jinjie
Chen, Jiaqi
Xu, Dong
Li, Jun
Yu, Yangyang
Song, Yunjie
Yuan, Ying
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] A phase II study of S-1 and irinotecan combination chemotherapy in patients with advanced gastric cancer as a first-line therapy
Ryoo, B. Y.
Kang, H. J.
Yang, S. H.
Cho, S. H.
Oh, S. J.
Lee, M. H.
Song, E. K.
Chung, H. C.
EJC SUPPLEMENTS, 2007, 5 (04): : 274 - 274
[40] Genetic variants in the Folic acid Metabolic Pathway Genes predict outcomes of metastatic Colorectal Cancer patients receiving first-line Chemotherapy
Jiang, Lu
Li, Shuwei
Yuan, Ming
Ma, Ling
Lin, Yu
Zhu, Weiyou
Du, Haina
Wang, Meilin
Chen, Tao
Zhu, Lingjun
JOURNAL OF CANCER, 2020, 11 (22): : 6507 - 6515

← 1 2 3 4 5 →